SCHEMBL21178152

SCHEMBL21178152

O[C@H]1CC[C@@H](c2nccs2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.40
AOC3 Q16853 2/20 0.39
ESR2 Q92731 2/20 0.35
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
TSHR P16473 2/20 0.33
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NOS1 P29475 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SPR P35270 2/20 0.32
FLT3 P36888 3/20 0.32
TYRO3 Q06418 3/20 0.32
MERTK Q12866 3/20 0.32
GAS6 Q14393 3/20 0.32
EPHX2 P34913 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21178115 1.00 DRD4 (0.40) DRD4AOC3ESR2ADORA3ADORA2A
SCHEMBL21178116 1.00 DRD4 (0.40) DRD4AOC3ESR2ADORA3ADORA2A
SCHEMBL498175 0.89
SCHEMBL24676709 0.89 DRD4 (0.36) DRD4AOC3ADORA3ADORA2AADORA2B
Formic Acid SCHEMBL28211550 0.82 DRD4 (0.39) DRD4AOC3ADORA3ADORA2AADORA2B
SCHEMBL2014387 0.82 ALDH1A1 (0.34) DRD4AOC3TSHRNOS3NOS2
SCHEMBL497630 0.81 TSHR (0.38) DRD4AOC3ADORA3ADORA2AADORA2B
SCHEMBL577126 0.81
SCHEMBL9830249 0.80 DRD4 (0.37) DRD4AOC3ESR2ADORA3ADORA2A
SCHEMBL25524077 0.80 ALDH1A1 (0.38) DRD4AOC3ADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12005127-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-06-11 US disclosed
CN-111757876-B DNA-PK inhibitors 沃泰克斯药物股份有限公司 2024-03-22 CN disclosed
EP-3740480-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2024-03-06 EP disclosed
US-20230063457-A1 DNA-PK INHIBITING COMPOUNDS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2023-03-02 US disclosed
WO-2021050059-A1 DNA-PK INHIBITING COMPOUNDS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2021-03-18 WO disclosed
EP-3740480-A1 DNA-PK INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2020-11-25 EP disclosed
US-20200353101-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2020-11-12 US disclosed
US-20200353101-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2020-11-12 US disclosed
CN-111757876-A DNA-PK inhibitors 沃泰克斯药物股份有限公司 2020-10-09 CN disclosed
WO-2019143678-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-07-25 WO disclosed
WO-2019143678-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230063457-A1 DNA-PK INHIBITING COMPOUNDS DCK, POLK, ERCC2 DRD4 4636/4885AOC3 4638/4885ESR2 1954/4885
US-20200353101-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK DRD4 4822/4885AOC3 4821/4885ESR2 2749/4885
US-12005127-B2 DNA-PK inhibitors POLK, DTYMK, DCK DRD4 4822/4885AOC3 4821/4885ESR2 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.